Chair: Perry Karsen, Celgene Cellular Therapeutics
Staff Contact: Amy Finan, Senior Vice President, Business Operations, firstname.lastname@example.org
Subject Matter/Jurisdiction: The committee provides guidance to BIO management on the organization’s business strategy regarding current and future non-dues revenue opportunities for the organization. This source of revenues is important to continuing BIO’s support of membership services and the organization’s advocacy mission. The Business Strategies & Innovations Committee of the BIO Board of Directors is organized structurally under the Full Board of Directors because its purview is cross-cutting in nature and not limited to one specific Section Governing Board.
Perry Karsen, Chief Executive Officer, Celgene Cellular Therapeutics
Thomas Mathers, CEO, CoLucid Pharmaceuticals Inc.
Douglas Doerfler, President & CEO, MaxCyte Inc.
Adam Monroe, President, Americas, Novozymes North America
Maxine Gowen, Chief Executive Officer, Trevena Inc.
Arlene Morris, President & CEO, Syndax Pharmaceuticals
Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.
John Orwin, Chief Executive Officer, Relypsa
John Johnson, Chairman, President & CEO, Dendreon
Kristine Peterson, Chief Executive Officer, Valeritas Inc.
Daniel Junius, President & CEO, ImmunoGen, Inc.
Timothy Walbert, Chairman, President & CEO, Horizon Pharma, Inc.
Emer Leahy, President & CEO, PsychoGenics Inc. & PGI Drug Discovery LLC
H. Thomas Watkins, Chair Emeritus, BIO
Klaus Wilgenbus, Corporate Senior Vice President, Boehringer Ingelheim Pharmaceuticals